Öz
Kaynakça
- Ballard CG, Waite J, Birks J (2006). Atypical antipsychotics for aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev (1).
- Burris KD, Molski TF, Xu C, Ryan E, Tottori K, et al. (2002). Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302(1): 381-389.
- Ellman GL, Courtney KD, Andres Jr V, Featherstone RM (1961). A new and rapid colorimetric determination of acetylcholinesterase activity. Biochemical pharmacology 7(2): 88-95.
- Lane RM, Kivipelto M, Greig NH (2004). Acetylcholinesterase and its inhibition in Alzheimer disease. Clin Neuropharmacol 27(3): 141-149.
- Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, et al. (2003). Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28(8): 1400-1411.
- Shukur KT, Ercetin T, Luise C, Sippl W, Sirkecioglu O, et al. (2021). Design, synthesis, and biological evaluation of new urolithin amides as multitarget agents against Alzheimer's disease. Archiv der Pharmazie 354(5): 2000467.
Synthesis of 7-(3-(4-(2,3-dichlorophenyl)piperazin-1-yl)propoxy)-3,4-dihydroquinolin-2(1H)-one and Screening Its Cholinesterase Inhibitor Properties
Öz
Aripiprazole is a well-known atypical antipsychotic drug [i.e., 7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one]. The pharmacological effects of aripiprazole are primarily attributed to its partial agonist activity at dopamine and serotonin receptors, although the exact mechanism of action remains unclear. However, it is generally accepted that aripiprazole exerts its therapeutic effects by modulating dopaminergic and serotoninergic neurotransmission. This study aimed to synthesize a modified derivative of aripiprazole and to investigate the cholinesterase inhibitory potential of this compound. The cholinesterase inhibition potential of the synthesized compound was evaluated using the Ellman’s method. The inhibitory activities against various cholinesterases were determined. The results indicated that the scaffold employed might be used for further cholinesterase inhibitor molecule design.
Anahtar Kelimeler
Alzheimer’s disease Antioxidant activity Aripiprazole Cholinesterase inhibition Modified Ellman’s method
Kaynakça
- Ballard CG, Waite J, Birks J (2006). Atypical antipsychotics for aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev (1).
- Burris KD, Molski TF, Xu C, Ryan E, Tottori K, et al. (2002). Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302(1): 381-389.
- Ellman GL, Courtney KD, Andres Jr V, Featherstone RM (1961). A new and rapid colorimetric determination of acetylcholinesterase activity. Biochemical pharmacology 7(2): 88-95.
- Lane RM, Kivipelto M, Greig NH (2004). Acetylcholinesterase and its inhibition in Alzheimer disease. Clin Neuropharmacol 27(3): 141-149.
- Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, et al. (2003). Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28(8): 1400-1411.
- Shukur KT, Ercetin T, Luise C, Sippl W, Sirkecioglu O, et al. (2021). Design, synthesis, and biological evaluation of new urolithin amides as multitarget agents against Alzheimer's disease. Archiv der Pharmazie 354(5): 2000467.
Ayrıntılar
| Birincil Dil | İngilizce |
|---|---|
| Konular | Eczacılık Bilimleri |
| Bölüm | Research Article |
| Yazarlar | |
| Yayımlanma Tarihi | 3 Temmuz 2025 |
| Gönderilme Tarihi | 12 Mayıs 2025 |
| Kabul Tarihi | 20 Haziran 2025 |
| Yayımlandığı Sayı | Yıl 2025 Cilt: 8 Sayı: 1 |
